性做久久久久久坡多野结衣-性做久久久久久久久浪潮-性欲影院-性影院-国产精品线路一线路二-国产精品兄妹在线观看麻豆

FMC63 scFv （single-chain variable fragment） is a recombinant protein derived from the variable regions （VH and VL） of the anti-CD19 monoclonal antibody FMC63, linked by a flexible peptide spacer （e.g., （Gly?Ser）?）. It specifically binds to the B-cell surface antigen CD19 with high affinity （KD ~1-10 nM） and is a key targeting component in FDA-approved CAR-T therapies, such as Kymriah?. The humanized FMC63 scFv retains potent antigen recognition while minimizing immunogenicity, making it highly effective in treating B-cell malignancies, including acute lymphoblastic leukemia （ALL） and non-Hodgkin lymphoma （NHL）. Ongoing research focuses on optimizing its affinity, stability, and functionality to enhance the safety and efficacy of CAR-T cell therapies.